An Incidental Liver Lesion: Hemangioma, FNH, or Something to Watch

The question that actually decides your next step is not how big the spot is. It is how the lesion behaves when contrast washes through it, and what the rest of your liver looks like underneath. Those two things, read together, separate a harmless hemangioma from a spot that earns a closer look. Healz was built to hold both halves of that picture at once.

Why a spot on your liver is usually nothing

Most incidental liver lesions are benign. Hemangiomas and simple cysts turn up all the time on abdominal ultrasound, CT, and MRI done for unrelated reasons. Hemangioma is the most common benign liver tumor, reported in about 5 percent of the adult population and more common in women, per the Cleveland Clinic and hepatic imaging reviews. Simple hepatic cysts are also common, with population ultrasound studies reporting them in a wide range, often rising after age 40.

The reason these show up so often is not that livers are getting sicker. It is that imaging has gotten sharper. A modern CT or MRI resolves millimeter-scale detail, so it catches things that were always there and never mattered. The finding is real. The alarm attached to it usually is not.

That does not mean every spot gets a shrug. It means the job is to characterize it: to figure out what the lesion actually is, using the tools that can tell benign from concerning. Panic is not a plan. Characterization is.

The three usual suspects: hemangioma, FNH, and cysts

Three benign entities account for most incidental solid or fluid-filled liver findings.

A hemangioma is a tangle of blood vessels. It is the most common benign liver tumor, it rarely grows in a way that matters, and it almost never turns into anything. On MRI it is bright on T2-weighted images and, with contrast, fills in from the outer edge toward the center over successive phases, a pattern distinctive enough that radiologists can often call it with confidence.

Focal nodular hyperplasia (FNH) is the second most common benign liver tumor, per the imaging literature. It is not a true tumor but an overgrowth of normal liver tissue around an abnormal artery, often with a central scar. It does not become cancer and is usually left alone once it is confidently identified. FNH lights up briskly in the arterial phase and, importantly, does not "wash out" the way a cancer would.

A simple cyst is a sac of fluid. On imaging it is sharply defined, does not take up contrast, and is essentially always benign. A related lesion, the hepatocellular adenoma, is less common, is associated with oral contraceptive and hormone use, and gets more attention because a small subset can bleed or, rarely, transform, so it is characterized carefully rather than ignored.

How contrast tells them apart

Plain imaging shows a spot. Contrast imaging shows how that spot behaves, and behavior is what carries the diagnosis. When contrast is injected, benign and malignant lesions light up and fade on different schedules, and that timing is the fingerprint.

Contrast-enhanced MRI, particularly with a liver-specific (hepatobiliary) agent, is considered the strongest tool for characterizing focal liver lesions in the hepatology imaging literature. It captures the arterial phase, the portal venous phase, and delayed and hepatobiliary phases, so a hemangioma's edge-to-center fill-in, an FNH's brisk uptake without washout, and a cyst's flat non-enhancement each read as a recognizable signature. A multiphase CT does much of the same work when MRI is not available.

This is why the impression line on a report matters less than the phases behind it. A single still image can look ambiguous. The enhancement pattern across phases is where the answer lives. If you have ever tried to make sense of the dense phase-by-phase description on a scan, our guide on how to read a CT scan report walks through what each section is actually telling you.

When the background liver changes the stakes: LI-RADS

Here is the part that gets lost: the same lesion means different things in different livers. A 2-centimeter spot in an otherwise healthy liver is read one way. The same spot in a liver scarred by cirrhosis or damaged by chronic hepatitis B is read with far more scrutiny, because that liver is already at elevated risk for hepatocellular carcinoma (HCC), the most common primary liver cancer.

For those at-risk livers, radiologists use LI-RADS, the Liver Imaging Reporting and Data System created with the support of the American College of Radiology (ACR). LI-RADS applies specifically to patients with cirrhosis or chronic hepatitis B, not to the general population, and it sorts observations onto a ladder of probability. LR-1 is definitely benign, the category that covers cysts and classic hemangiomas. LR-5 is definitely HCC. The categories in between reflect rising probability, scored on major features the ACR defines: arterial-phase hyperenhancement, size, washout, capsule appearance, and growth over time. The system is designed so that an LR-5 read is highly specific for cancer, and it is integrated with the American Association for the Study of Liver Diseases (AASLD) HCC guidance.

The practical takeaway is that context is not a footnote. Two identical-looking spots can land on opposite ends of the risk ladder purely because of the liver they sit in. That is why a good workup never reads the lesion in isolation. If your finding came with the words "incidental" or "indeterminate," our guide on what to do about an incidental finding covers how the follow-up decision is actually made.

How Healz reads a liver lesion in full context

A liver finding is really two questions answered together. What does the lesion look like across the contrast phases, and what is the liver it sits in? Read either one alone and you get half an answer. Healz is built to hold both at once.

Healz is equipped with Frontier AI, so when you upload your CT or MRI report it reads the enhancement pattern and your background-liver context in the same pass, not as separate facts. It flags whether the description fits a classic benign hemangioma, an FNH-type pattern, or an observation that belongs on the LI-RADS ladder given your history of hepatitis or cirrhosis. That is what turns an alarming line on a page into a clear next step. This is the kind of online mri report analysis ai and ai ct scan analysis that reads the whole picture, not one still frame.

Healz has memory, so it remembers what your last scan showed and connects the dots across time. A liver lesion is often a question of change: stable over years usually means benign, while new growth is what earns attention. Healz holds your prior imaging and compares, so "has this moved?" is answered from your own record instead of guessed. And Healz is equipped with root-cause technology, so it cross-checks your case against a large body of rare and complex cases and asks the questions a rushed read can skip, everything in one chat instead of ten scattered apps. When you want a human in the loop, you can bring a board-certified doctor into the same chat for a second opinion.